Now that the Fed rate hike has passed, how long will the market continue to give the "Trump rally" the benefit of the doubt?
There's a simple reason for why the stock market rallied after the Fed raised rates as expected.
A new report from OPEC spells even more trouble for struggling oil companies.
There's a very good reason market capitalization is still king when it comes to indexing.
Target shares experienced the same pain Wal-Mart felt when it said it would invest billions in the business.
The world's largest retailer will begin rolling out two features to its mobile app that take aim at Target and Amazon's weaknesses.
Rising tensions between Trump and the Fed have traders scratching their heads.
J.C. Penney CEO Marvin Ellison doesn't think a border adjustment tax is a foregone conclusion.
Buybacks keep rolling along, but here is why they are no panacea for all of the market's problems.
Bill Smead, Smead Capital Management shares his trade on housing and a pharmaceutical supply chain
Traders may want to think twice before backing out of the reflation trade right now.
The earnings boosts fueled by tax cuts may not be quite as great as everyone had hoped.
The Fed is staying as flexible as possible by maintaining a more dovish tone than the markets expected.
The new terms set shares of Rite Aid at a maximum of $7 per share and $6.50 minimum, down from the initial $9 Walgreens agreed to purchase.
CNBC's Seema Mody reports the latest on the takeover deal between Walgreens and Rite Aid.
Walgreens lowered its acquisition price for the retail pharmacy chain's shares.
The cost that comes with government lies is greater than you think, says Dustin McKissen.
Shares of Walgreen Boots Alliance and Rite Aid are trading lower after the merger of the two drugstore companies is facing US antitrust concerns.
The market is a "coiled spring" right now and bank earnings could push stocks past the tipping point.
Is the bank run overdone? Analysts are sounding a note of caution ahead of Q4 earnings.